Clinical Trial Update: A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

View source ↗

Summary

Registry study evaluating patient-reported outcomes, dosing patterns, and safety of Vunakizumab in several rheumatic diseases; recruitment has not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Behçet Disease
• Enthesitis-related Arthritis
• Giant Cell Arteritis
• Non-radiographic Axial Spondyloarthritis
• Polymyalgia Rheumatica
• Psoriatic Arthritis
• Takayasu Arteritis

Drugs mentioned

• Vunakizumab (Vunakizumab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | Status: NOT_YET_RECRUITING